成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读  

Interpretation of“Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults:an official ATS/ERS/JRS/ALAT clinical practice guideline(2022 edition)”

作　　者：于娜[1] 周家为 李霞[1] 张婷[1] 刘紫艳 Yu Na;Zhou Jia-wei;Li Xia;Zhang Ting;Liu Zi-yan(The First Hospital of China Medical University,Department of Pulmonary and Critical Care Medicine,Institute of Respiratory Disease,Shenyang,Liaoning 110001,China)

机构地区：[1]中国医科大学附属第一医院呼吸与危重症医学科,辽宁沈阳110001

出　　处：《中国现代医学杂志》2023年第14期1-8,共8页China Journal of Modern Medicine

基　　金：辽宁省科技厅支持中国医科大学高质量发展科技资金项目(No:1686040363153)。

摘　　要：2022年5月美国胸科学会(ATS)、欧洲呼吸学会(ERS)、日本呼吸学会(JRS)、拉丁美洲胸科协会(ALAT)四大学会联合发表成人特发性肺纤维化(IPF)(更新)和进行性肺纤维化(PPF)临床实践指南,该指南对2018版ATS、ERS、JRSALAT发布的IPF临床实践指南进行部分更新,并提出了PPF的定义。在2022版成人IPF和PPF临床实践指南发布近1周年之际,该文重新审视并解读指南变更对间质性肺疾病临床研究及实践的影响,进一步探讨未来IPF、PPF领域可能的发展方向及热点。In May 2022,American Thoracic Society(ATS),European Respiratory Society(ERS),Japanese Respiratory Society(JRS)and Latin American Thoracic Society(ALAT)jointly published“Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults:an official ATS/ERS/JRS/ALAT clinical practice guideline”,which partially updated the guideline released by ATS/ERS/JRS/ALAT in 2018 and put forward a new definition of“progressive pulmonary fibrosis(PPF)”.On the anniversary of the publication of the 2022 guideline,this article rethinks and interprets the impact of the amendments to the guideline on the clinical research and practice concerning interstitial lung diseases,and further discusses the potential direction of development and future trends in the field of idiopathic pulmonary fibrosis(IPF)/PPF.

关 键 词：间质性肺疾病 特发性肺纤维化 进行性肺纤维化 指南 

分 类 号：R563[医药卫生—呼吸系统]